Trial · NCT00129766
Adverse events688
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 688
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Palivizumab | 73 | 3,298 | 75 |
| other | ANAEMIA | Blood and lymphatic system disorders | Motavizumab | 66 | 3,315 | 67 |
| other | DACRYOSTENOSIS CONGENITAL | Congenital, familial and genetic disorders | Palivizumab | 33 | 3,298 | 34 |
| other | DACRYOSTENOSIS CONGENITAL | Congenital, familial and genetic disorders | Motavizumab | 35 | 3,315 | 37 |
| other | CONJUNCTIVITIS | Eye disorders | Palivizumab | 251 | 3,298 | 285 |
| other | CONJUNCTIVITIS | Eye disorders | Motavizumab | 246 | 3,315 | 271 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Palivizumab | 70 | 3,298 | 73 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Motavizumab | 54 | 3,315 | 55 |
| other | CONSTIPATION | Gastrointestinal disorders | Palivizumab | 227 | 3,298 | 262 |
| other | CONSTIPATION | Gastrointestinal disorders | Motavizumab | 234 | 3,315 | 265 |
| other | DIARRHOEA | Gastrointestinal disorders | Palivizumab | 274 | 3,298 | 306 |
| other | DIARRHOEA | Gastrointestinal disorders | Motavizumab | 254 | 3,315 | 295 |
| other | FLATULENCE | Gastrointestinal disorders | Palivizumab | 119 | 3,298 | 135 |
| other | FLATULENCE | Gastrointestinal disorders | Motavizumab | 126 | 3,315 | 170 |
| other | GASTROOESOPHAGEAL REFLUX DISEASE | Gastrointestinal disorders | Palivizumab | 190 | 3,298 | 198 |
| other | GASTROOESOPHAGEAL REFLUX DISEASE | Gastrointestinal disorders | Motavizumab | 190 | 3,315 | 197 |
| other | TEETHING | Gastrointestinal disorders | Palivizumab | 282 | 3,298 | 408 |
| other | TEETHING | Gastrointestinal disorders | Motavizumab | 299 | 3,315 | 417 |
| other | UMBILICAL HERNIA | Gastrointestinal disorders | Palivizumab | 63 | 3,298 | 63 |
| other | UMBILICAL HERNIA | Gastrointestinal disorders | Motavizumab | 77 | 3,315 | 77 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00129766/events